Search Results 1881-1890 of 19658 for hemoglobin

  1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

    hemoglobin ≥ 8.5 g/dL without transfusion in the previous week;; creatinine ≤ 1.5 x upper limit of normal (ULN);; aspartate aminotransferase AST (SGOT) ≤ 3 ...

  2. Pirtobrutinib And Venetoclax With MRD Detection For Previously Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

    * Hemoglobin \>= 8 g/dL (obtained =\< 14 days prior to registration) * Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and ...

  3. A Study of TAS-120 in Patients With Metastatic Breast Cancer - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL without transfusion support (that is, excluding measurements within 7 days after transfusion of packed red blood cells or whole blood); ...

  4. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC - Mayo Clinic

    purposes). 8. Patients must have adequate organ function: - Bone marrow reserve ANC ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥9 g/dL - Hepatic ...

  5. A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology (Veri-T-001) - Mayo Clinic

    Hemoglobin A1C > 7.5% at screening (confirmed by repeat);. Current or recent history (within four weeks prior to initial screening visit) of a clinically ...

  6. A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer - Mayo Clinic

    Hemoglobin < 9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed. Serum ...

  7. A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL;; Absolute neutrophil count (ANC) ≥ 1000/mm^3;; Platelet count ≥ 100,000/mm^3;; Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ...

  8. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  9. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  10. Publications - Amy C. Clayton, M.D. - Mayo Clinic

    A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May ...